Eli was diagnosed with an eye condition called PHPV as an infant, which resulted in a detached retina at 12 months of age. Later, at age 5, he was diagnosed with NF2.More >
The Children's Tumor Foundation's mission is to drive research, expand knowledge, and advance care for the NF community.
Since its formation, the Children’s Tumor Foundation has been crucial to the development of solid scientific data about the genetic disorder neurofibromatosis (NF). Thanks to the generosity of our donors and supporters, we are breaking through barriers and forging the pathway that will lead to a cure.
The Children's Tumor Foundation is excited to announce that it has once again been honored with a 4-star rating from Charity Navigator, America's largest and most-utilized independent evaluator of philanthropies.More >
AstraZeneca and Merck today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). Selumetinib was shown to be effective in shrinking tumors because of an early-stage investment of the Children Tumor Foundation. Over 70% of participants in this MEK clinical trial are showing reductions in tumor size from 20-50% of their inoperable plexiform neurofibromas.More >
Join us November 2-6, 2018 in Paris, France for the Joint Global Neurofibromoatosis Conference, a global event attracting more than 800 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis.More >